Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings is viewed favorably because its bookings momentum is improving, with RFPs up meaningfully both quarter-over-quarter and year-over-year, win rates rising, and management expecting gross and net bookings to improve through the rest of '26 even in almost any cancellation scenario. The company’s shift back toward oncology from cardiometabolic work and its pre-backlog pipeline, which has been growing faster than backlog and feeds bookings with a roughly three-quarter lag, suggest a healthier mix and stronger visibility into 2H26 and 2027 growth. Its leadership position as a highly efficient CRO, with more than 5,400 employees across 40 countries and a business that remains heavily exposed to biopharma demand, supports expectations for continued revenue and EPS expansion.

Medpace Holdings is viewed negatively because its business is highly exposed to biopharma funding cycles, regulatory slowdowns, and macro weakness that can delay, reduce, or cancel clinical trial activity. The excerpts also highlight operational execution risk from slower-than-expected patient enrollment, site selection issues, talent shortages, and data security failures, any of which could damage sponsor confidence and pressure bookings. Although pass-throughs are now expected north of 42% in FY with a 41-42% target for 3Q and 4Q, elevated cancellations and AI-driven automation could still compress project scope and limit margin durability.